Showing results (231-240 of 326) with videos related to

Sort By:
Pageof 33
Transplantation and Cellular Therapy|June 9, 2021
The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple MyelomaSarah A Holstein, Nizar Bahlis, P Leif Bergsagel, et al.
Leukemia|May 28, 2020
Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumabTineke Casneuf, Homer C Adams, Niels W C J van de Donk, et al.
Eclinicalmedicine|March 10, 2023
Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: a prospective observational cohort studyNeha Korde, Elizabet Tavitian, Donna Mastey, et al.
Blood Cancer Journal|May 31, 2024
Comparison of infectious complications with BCMA-directed therapies in multiple myelomaKarthik Nath, Tala Shekarkhand, David Nemirovsky, et al.
The New England Journal of Medicine|October 6, 2016
Daratumumab, Lenalidomide, and Dexamethasone for Multiple MyelomaMeletios A Dimopoulos, Albert Oriol, Hareth Nahi, et al.
European Journal of Haematology|February 14, 2025
Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported OutcomesAurore Perrot, Thierry Facon, Torben Plesner, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 26, 2026
Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific AntibodiesIssam S Hamadeh, Maximillian Merz, Andriy Derkach, et al.
The Lancet. Haematology|October 10, 2022
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label studyThomas Martin, Yi Lin, Mounzer Agha, et al.
The Lancet. Haematology|July 23, 2019
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trialMaria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, et al.
JCO Oncology Practice|September 16, 2025
Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up DosesIssam S Hamadeh, Lisa Modelevsky, Amelia Chan, et al.
Pageof 33